Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 13


Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL.

J Clin Oncol. 2015 Oct 20;33(30):3416-22. doi: 10.1200/JCO.2014.58.8533. Epub 2015 Aug 17.


Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.

Irving GR, Iwuji CO, Morgan B, Berry DP, Steward WP, Thomas A, Brown K, Howells LM.

Trials. 2015 Mar 24;16:110. doi: 10.1186/s13063-015-0641-1.


Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.

Deuis JR, Lim YL, Rodrigues de Sousa S, Lewis RJ, Alewood PF, Cabot PJ, Vetter I.

Neuro Oncol. 2014 Oct;16(10):1324-32. doi: 10.1093/neuonc/nou048. Epub 2014 Apr 8.


Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group.

J Natl Cancer Inst. 2014 Mar 12;106(5). pii: dju044. doi: 10.1093/jnci/dju044. Review.


Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.

Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90.


Effects of oxaliplatin on mouse myenteric neurons and colonic motility.

Wafai L, Taher M, Jovanovska V, Bornstein JC, Dass CR, Nurgali K.

Front Neurosci. 2013 Mar 12;7:30. doi: 10.3389/fnins.2013.00030. eCollection 2013.


Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.

Zhu Y, Yang J, Jiao S, Ji T.

World J Surg Oncol. 2013 Jan 25;11:19. doi: 10.1186/1477-7819-11-19.


Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.

Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G.

Support Care Cancer. 2012 Apr;20(4):877-81. doi: 10.1007/s00520-011-1336-0. Epub 2011 Dec 9.


Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?

Cavaletti G.

Oncologist. 2011;16(12):1667-8. doi: 10.1634/theoncologist.2011-0343. Epub 2011 Nov 29. No abstract available.


Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy.

Alvarez P, Ferrari LF, Levine JD.

Ann Neurol. 2011 Jul;70(1):101-9. doi: 10.1002/ana.22382.


Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice.

Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, Cavaletti G.

Mol Pain. 2011 Apr 26;7:29. doi: 10.1186/1744-8069-7-29.


Oxaliplatin-Related Ocular Toxicity.

Mesquida M, Sanchez-Dalmau B, Ortiz-Perez S, Pelegrín L, Molina-Fernandez JJ, Figueras-Roca M, Casaroli-Marano R, Adán A.

Case Rep Oncol. 2010 Nov 22;3(3):423-427.


Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli.

Ta LE, Low PA, Windebank AJ.

Mol Pain. 2009 Feb 26;5:9. doi: 10.1186/1744-8069-5-9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk